Form 4: Lixte Biotechnology Director Regina Brown Acquires Stock Options in Lieu of Cash Compensation

Director Regina Brown acquired 9,508 stock options in Lixte Biotechnology Holdings, Inc. on March 31, 2025, in lieu of quarterly cash compensation.

Summary

• Regina Brown, a director of Lixte Biotechnology Holdings, Inc., acquired 9,508 stock options on March 31, 2025.
• These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan.
• The options have an exercise price of $1.21 and expire on March 31, 2030.
• Brown directly owns these options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director's acceptance of stock options in lieu of cash compensation suggests confidence in the company's future prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

In the biotechnology industry, stock options are a common form of compensation for directors and executives, aligning their interests with those of shareholders.

Related Party Transactions

• The grant of stock options to Regina Brown, a director, in lieu of cash compensation is a related party transaction.

Stakeholder Impact

• Shareholders may view the director's acceptance of stock options as a positive sign, aligning her interests with theirs.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, director, Lixte Biotechnology, Regina Brown, compensation, Form 4, beneficial ownership